PMID- 33319048
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2397-9070 (Electronic)
IS  - 2397-9070 (Linking)
VI  - 4
IP  - 6
DP  - 2020 Dec
TI  - Sorafenib as second-line treatment option after failure of lenvatinib in patients 
      with unresectable hepatocellular carcinoma.
PG  - 1135-1139
LID - 10.1002/jgh3.12408 [doi]
AB  - BACKGROUND AND AIM: Currently, there is no molecular-targeted agent that has 
      demonstrated evidence of efficacy in patients with unresectable hepatocellular 
      carcinoma (u-HCC) who have developed resistance to treatment with lenvatinib 
      (LEN). In this real-world study, we aimed to investigate the therapeutic effect 
      and safety of sorafenib (SOR) in patients with u-HCC after progression on 
      treatment with LEN. METHODS PATIENTS AND RESULTS: A total of 13 patients with 
      u-HCC (12 males and 1 female), who were treated with SOR after progression on 
      LEN, were enrolled in this retrospective study. Therapeutic efficacy was 
      evaluated via contrast-enhanced computerized tomography at 8 weeks after the 
      initiation of SOR therapy according to modified response evaluation criteria in 
      solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response 
      rate (ORR) and disease control rate (DCR) were 15.3% (2/13) and 69.2% (9/13), 
      respectively. According to RECIST, the ORR and DCR were 0% (0/13) and 69.2% 
      (9/13), respectively. The median progression-free survival was 4.1 months. The 
      median albumin-bilirubin scores did not deteriorate significantly at 4, 6, and 
      8 weeks after initiation of SOR, compared with the scores at the baseline. The 
      most frequent grade 1 or 2 adverse events (AEs) were palmar-plantar 
      erythrodysesthesia, fatigue, diarrhea, and hypertension. There was no incidence 
      of grade 3 AEs. CONCLUSION: Treatment with SOR may be effective for u-HCC after 
      failure on LEN and may not worsen the liver reserve.
CI  - (c) 2020 The Authors. JGH Open published by Journal of Gastroenterology and 
      Hepatology Foundation and John Wiley & Sons Australia, Ltd.
FAU - Tomonari, Tetsu
AU  - Tomonari T
AUID- ORCID: 0000-0002-8484-9866
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
FAU - Sato, Yasushi
AU  - Sato Y
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
FAU - Tanaka, Hironori
AU  - Tanaka H
AUID- ORCID: 0000-0003-4712-0192
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
FAU - Tanaka, Takahiro
AU  - Tanaka T
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
FAU - Taniguchi, Tatsuya
AU  - Taniguchi T
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
FAU - Sogabe, Msasahiro
AU  - Sogabe M
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
FAU - Okamoto, Koichi
AU  - Okamoto K
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
FAU - Miyamoto, Hiroshi
AU  - Miyamoto H
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
FAU - Muguruma, Naoki
AU  - Muguruma N
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
FAU - Takayama, Tetsuji
AU  - Takayama T
AD  - Department of Gastroenterology and Oncology, Institute of Biomedical Sciences 
      Tokushima University Graduate School Tokushima Japan.
LA  - eng
PT  - Journal Article
DEP - 20200815
PL  - Australia
TA  - JGH Open
JT  - JGH open : an open access journal of gastroenterology and hepatology
JID - 101730833
PMC - PMC7731817
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - lenvatinib
OT  - ramucirumab
OT  - regorafenib
OT  - sorafenib
EDAT- 2020/12/16 06:00
MHDA- 2020/12/16 06:01
PMCR- 2020/08/15
CRDT- 2020/12/15 06:05
PHST- 2020/07/10 00:00 [received]
PHST- 2020/07/30 00:00 [revised]
PHST- 2020/08/02 00:00 [accepted]
PHST- 2020/12/15 06:05 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2020/12/16 06:01 [medline]
PHST- 2020/08/15 00:00 [pmc-release]
AID - JGH312408 [pii]
AID - 10.1002/jgh3.12408 [doi]
PST - epublish
SO  - JGH Open. 2020 Aug 15;4(6):1135-1139. doi: 10.1002/jgh3.12408. eCollection 2020 
      Dec.